Efficacy and Safety of Prophylactic-Dose Anticoagulation Therapy with Intermediate-Therapeutic Doses in Covid-19 Patients
DOI:
https://doi.org/10.37506/ijfmt.v17i1.18902Keywords:
: COVID-19, thromboprophylaxis, anticoagulants, thrombosis, bleedingAbstract
Introduction: Coronavirus Disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2
(SARSCoV-2) was declared a worldwide pandemic on March 11, 2020 and globally, on April 29, 2022, there were
510,270,667 confirmed COVID-19 cases, including 6,233,526 deaths, reported to WHO. As of April 2022, the
Government of the Republic of Indonesia has reported 4,249,323 confirmed cases of COVID-19. There have been
143,592 COVID-19-related deaths reported and 4,096,194 patients have recovered from the disease. COVID-19
is associated with a high risk of venous thromboembolism (VTE), however, to date, optimal prophylactic
anticoagulant therapy remains uncertain and may depend on the severity of COVID-19.
Objective: The aim of this study was to determine the difference in efficacy and safety in administering prophylactic
doses with intermediate/therapeutic doses in confirmed COVID-19 patients.
Results: This study used 6 studies that met the inclusion of differences in efficacy and safety in administering
prophylactic doses with intermediate/therapeutic doses in confirmed COVID-19 patients.
Conclusion: From 6 studies, there were 2 studies comparing anticoagulant prophylactic doses with intermediate
doses and 4 studies comparing anticoagualnt prophylactic doses with therapeutic doses. In all studies, there were
no significant differences in thromboembolic events or all-cause mortality in COVID-19 patients. The incidence of
bleeding at the intermediate and therapeutic doses increased compared to the prophylactic dose, but the difference
was not significant.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en